China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
REDWOOD CITY, Calif., Feb. 22, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that the Company will be participating in two upcoming investor conferences.
Avinger’s management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 11:20am ET.
Avinger’s management is also scheduled to present at the Oppenheimer 27th Annual Healthcare Conference in New York, NY on Wednesday, March 22, 2017 at 10:20am ET.
Interested parties can access the live audio webcast with accompanying slides for both of these presentations on the Events section of Avinger’s website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
